China approves first AI-assisted Class 1 innovative drug, Mprosevir for COVID-19

China's drug regulator has approved Mprosevir, the first 'Class 1' innovative drug developed with AI assistance, for COVID-19 treatment. The drug's development from candidate discovery to clinical trial completion took 3.5 years, significantly shorter than traditional timelines. This marks a milestone for AI-driven drug discovery, though the report does not specify the AI methods used or the drug's efficacy data.